AHCO
Get informed when a big investor buys or sells
+ FollowUndervalued by 62.2% based on the discounted cash flow analysis.
| Market cap | $1.38 Billion |
|---|---|
| Enterprise Value | $3.39 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.52 |
| Beta | 1.57 |
| Outstanding Shares | 135,779,000 |
| P/E Ratio | -17.27 |
|---|---|
| PEG | -14.09 |
| Price to Sales | 0.39 |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | 0.97 |
| Enterprise Value to EBIT | 46.34 |
| Enterprise Value to Net Income | -42 |
| Total Debt to Enterprise | 0.61 |
| Debt to Equity | 1.37 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.7778▲ 2.68% |
|---|---|
| Total Calls | 672,900▼ 63.50% |
| Total Puts | 1,869,200▼ 63.14% |
Holdings and activity of institutional investors.
| Ownership % | 104.27%▲ 1.50% |
|---|---|
| Total Invested | $1.68B▲ 21.24% |
| Investors Holding | 249▲ 1.00% |
No data
This powerful committee controls taxation, trade, and entitlement spending, directly influencing Medicare pricing and overall federal healthcare funding, which are critical revenue streams and regulatory factors for AdaptHealth.
This committee directly allocates federal discretionary spending. Its decisions on funding for federal healthcare programs (e.g., Medicare, Medicaid, VA) directly impact the reimbursement and purchasing power for AdaptHealth's products.
This committee regulates the FDA, which oversees medical devices that AdaptHealth distributes. Its influence on healthcare policy, drug approvals, and labor laws directly impacts AdaptHealth's operating environment and the products it handles.
AdaptHealth, as a medical equipment and supplies wholesaler, would directly benefit or be impacted by funding decisions and procurement policies affecting the Department of Veterans Affairs (VA), a potential major customer.